Migenix to begin clinical trial of celgosivir in Q2

By Ted A. Knutson

Washington, Jan. 23 - Migenix Inc. said the company plans to begin a combination therapy viral kinetics clinical trial of celgosivir (MX-3253) in patients with the hepatitis C virus in the second quarter.

Celgosivir is an orally administered, first-in-class alpha glucosidase 1 inhibitor in development for the treatment of chronic hepatitis C virus infections.

The viral kinetics study is intended to demonstrate improved viral load kinetics, or antiviral activity, in treatment-naïve hepatitis C virus patients when celgosivir is used in combination with interferon over a treatment period of up to 28 days.

"This viral kinetics study provides us another significant clinical result in [hepatitis C virus] patients in 2006. In mid-year 2006 we will have results from our MX-3253 phase 2b study in [hepatitis C virus] 'non-responder' patients initiated in November 2005 with support from Schering-Plough. These results, along with the CPI-226 phase 3 clinical results expected in the first half of 2007 provide us several near-term value driving opportunities," Dr. Jim DeMesa, president and chief executive officer of Migenix, said in a news release.

Results are expected in the second half of the year.

Migenix is a San Diego, Calif.-based developer of drugs for infectious and degenerative diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.